Dashboard

Solid News

Pfizer Inc. Fourth-quarter Earnings may Decline

1/30/2023 2:40 PM

Shares of Pfizer Inc., the largest US pharmaceutical company, are correcting at 44.00.

The negative dynamics are developing against the backdrop of falling demand for the company's products due to the relative stabilization of the situation with the spread of coronavirus infection in the world: yesterday, one of the leading analytical agencies, UBS Group AG, revised its issuer rating from Buy to Neutral, lowering the target share price to 47.0 dollars from 55.0 dollars. The experts' decision was influenced by reports from the World Health Organization (WHO) that the number of new cases of COVID-19 is decreasing, as well as their severity, and therefore the urgent need for a large number of vaccine doses has disappeared.

Tomorrow, Pfizer Inc.'s financial report is expected to be higher than previous numbers, with revenue likely to be 24.61B dollars, up from 22.6B dollars a quarter earlier, but earnings per share will fall to 1.07, below 1.78 dollars in the previous quarter, reflecting a drop in demand for the company's products in recent months.


On the daily chart, the trading instrument falls within the corrective wave, approaching the last year's low, around 41.00.

Technical indicators maintain a sell signal: fast EMAs of the Alligator indicator are well below the signal line, and the AO histogram decreases, forming bars below the transition level.

Resistance levels: 45.00, 48.00. | Support levels: 43.00, 40.00.

Find Us
Registered Address : Bonovo Road – Fomboni Island of Mohéli – Comoros Union
Sofia, PO Box 1407,14 Flip Kutev Str. Floor 2, Industrial area Hladilnika, Bulgaria
Mail Us
[email protected]
Call Us
+35 924 928 392


Risk Warnings
Solid ECN Securities LLC offers trading on Foreign Exchange (‘Forex’ or ‘FX’) and Contracts for Difference (‘CFDs’), which are complex financial products that are traded on margin. They carry a high level of risk since leverage can work both to your advantage and disadvantage. As a result, these products may not be suitable for all investors, as loss of all invested capital may occur. You should not risk more than you are prepared to lose. Before deciding to trade, you need to ensure that you understand the risks involved and consider your investment objectives and level of experience. Seek independent advice, if necessary.
Solid ECN Securities LLC does not issue advice, recommendations or opinions in relation to acquiring, holding or disposing of a CFD. Solid ECN Securities LLC is not a financial advisor and all services are provided on an execution-only basis. This communication is not an offer or solicitation to enter into a transaction and shall not be construed as such.
This website is not directed at any jurisdiction and is not intended for any use that would be contrary to local law or regulation.
By using solidecn.com you agree to use our cookies to enhance your experience.
Solid ECN Securities LLC is authorized and regulated by the Comoros Union with reference number HY00623411.
Disclaimer 1: The information provided on this site is not intended for residents of any country or jurisdiction where its distribution or use would violate local laws or regulations.
Disclaimer 2: Solid ECN Securities LLC and it affiliates does not provide services to residents of the USA, Japan, Canada, Australia, the Democratic Republic of Korea, European Union, United Kingdom, Iran, Syria, Sudan and Cuba.
Copyright All Right Reserved 2024 SolidECN.com